{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:19:49Z","timestamp":1790878789220,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.urolonc.2021.05.017","type":"journal-article","created":{"date-parts":[[2021,6,13]],"date-time":"2021-06-13T16:48:53Z","timestamp":1623602933000},"page":"678-685","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Cyclophosphamide-associated bladder cancers and considerations for survivorship care: A systematic review"],"prefix":"10.1016","volume":"39","author":[{"given":"Wesley H.","family":"Chou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe L.F.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Kibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Mossanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2021.05.017_bib0001","doi-asserted-by":"crossref","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0002","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/art.25061","article-title":"Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review","volume":"62","author":"Monach","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0003","doi-asserted-by":"crossref","DOI":"10.2165\/00002018-200022040-00002","article-title":"Cardiotoxicity of chemotherapeutic agents. Incidence, treatment and prevention","author":"Pai","year":"2000","journal-title":"Drug Safety"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0004","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/ajd.12406","article-title":"Cyclophosphamide in dermatology","volume":"58","author":"Kim","year":"2017","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0005","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/jnci\/87.7.524","article-title":"Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma","volume":"87","author":"Travis","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0006","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-124-5-199603010-00003","article-title":"Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis","volume":"124","author":"Talar-Williams","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0007","doi-asserted-by":"crossref","DOI":"10.3109\/00365598709180320","article-title":"Recurrence, progression and survival in bladder cancer","author":"Malmstr\u00f6m","year":"1987","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0008","article-title":"Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of eight years","author":"Bergkvist","year":"1965","journal-title":"Acta Chir Scand"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2009.06.028","article-title":"Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy","author":"van Rhijn","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.2910630102","article-title":"Bladder tumours following chemotherapy and radiotherapy for ovarian cancer: a case\u2014control study","author":"Kaldor","year":"1995","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0011","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.2910230518","article-title":"Carcinogenic action of low-dose cyclophosphamide given orally to sprague-dawley rats in a lifetime experiment","author":"Schm\u00e4hl","year":"1979","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0012","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/1097-0142(19830215)51:4<606::AID-CNCR2820510409>3.0.CO;2-S","article-title":"Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2\u2019-dithio-bis-ethane sulfonate (dimesna)","volume":"51","author":"Habs","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/S0305-7372(83)80008-5","article-title":"Prevention of cyclophosphamide-induced carcinogenesis in the urinary bladder of rats by administration of mesna","author":"Schm\u00e4hl","year":"1983","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0014","article-title":"An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancer","author":"Ling","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.urology.2016.07.030","article-title":"Review of advances in uroprotective agents for cyclophosphamide- and ifosfamide-induced hemorrhagic cystitis","volume":"100","author":"Matz","year":"2017","journal-title":"Urol"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0016","article-title":"p53 mutations in cyclophosphamide-associated bladder cancer","author":"Khan","year":"1998","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2015.08.037","article-title":"Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes","author":"Dobruch","year":"2016","journal-title":"Euro Urol"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2019.09.003","article-title":"What is the significance of variant histology in urothelial carcinoma?","author":"Lobo","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0019","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/jcp.2010.077883","article-title":"Leiomyosarcoma of the urinary bladder: a clinicopathological study of 34 cases","volume":"63","author":"Lindberg","year":"2010","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0020","first-page":"3853","article-title":"Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder","volume":"48","author":"Kantor","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0021","doi-asserted-by":"crossref","DOI":"10.1097\/00005392-199805000-00023","article-title":"Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases","author":"Lopez-Beltran","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0022","series-title":"National Cancer Institute: Surveillance, Epidemiology, and End Results Program","year":"2020"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0023","doi-asserted-by":"crossref","DOI":"10.14740\/wjon1210","article-title":"Non-muscle invasive bladder cancer: a review of the current trend in Africa","author":"Cassell","year":"2019","journal-title":"World J Oncol"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0024","first-page":"397","article-title":"p53 mutations in cyclophosphamide-associated bladder cancer","volume":"7","author":"Khan","year":"1998","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0025","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780180113","article-title":"The effect of cyclophosphamide on b and t lymphocytes in patients with connective tissue diseases","author":"Hurd","year":"1975","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/0090-4295(78)90154-1","article-title":"Does cyclophosphamide induce bladder cancer?","author":"Pearson","year":"1978","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0027","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archophthalmol.2010.126","article-title":"Review of 676 second primary tumors in patients with retinoblastoma: association between age at onset and tumor type","volume":"128","author":"Woo","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0028","doi-asserted-by":"crossref","first-page":"E51","DOI":"10.5489\/cuaj.1162","article-title":"Intermittent self-catheterization and the risk of squamous cell cancer of the bladder: an emerging clinical entity?","volume":"3","author":"Casey","year":"2009","journal-title":"J Can Urol Assoc"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0029","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0022-5347(01)63185-9","article-title":"Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide","volume":"159","author":"De Ridder","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0030","first-page":"48","article-title":"Chemoprotectants for cancer chemotherapy","volume":"18","author":"Dorr","year":"1991","journal-title":"Semin Oncol"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0031","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","article-title":"Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis","volume":"340","author":"Boumpas","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0032","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"De Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0033","article-title":"Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis","author":"Faurschou","year":"2015","journal-title":"Rheumatol (United Kingdom)"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0034","first-page":"121","article-title":"Invasive bladder cancer after cyclophosphamide administration for nephrotic syndrome\u2013a case report","volume":"49","author":"Nakamoto","year":"2000","journal-title":"Hiroshima J Med Sci"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0035","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/003655901750292060","article-title":"Leiomyosarcoma of the bladder fourteen years after cyclophosphamide therapy for retinoblastoma","volume":"35","author":"Motta","year":"2001","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0036","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0090-4295(02)01701-6","article-title":"Leiomyosarcoma in urinary bladder after cyclophosphamide therapy for retinoblastoma and review of bladder sarcomas","volume":"60","author":"Parekh","year":"2002","journal-title":"Urol"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0037","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO Guideline","author":"Chang","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.05.017_bib0038","unstructured":"Microhematuria: AUA\/SUFU Guideline - American Urological Association. Available at: https:\/\/www.auanet.org\/guidelines\/microhematuria."}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921002234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921002234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:22:19Z","timestamp":1761042139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143921002234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1078143921002234"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.05.017","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclophosphamide-associated bladder cancers and considerations for survivorship care: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}